The entry of tetanus and botulinum neurotoxins into neurons by Pirazzini, Marco
  
 
 
 
 
Università degli Studi di Padova 
Dipartimento di Scienze Biomediche 
___________________________________________________________________ 
 
 
 
SCUOLA DI DOTTORATO DI RICERCA IN BIOSCIENZE E BIOTECNOLOGIE 
INDIRIZZO DI BIOLOGIA CELLULARE 
CICLO XXV 
 
 
 
 
 
The entry of tetanus and botulinum neurotoxins into neurons 
 
 
 
 
 
 
 
Direttore della Scuola : Ch.mo Prof. Giuseppe Zanotti 
Ch.mo Prof. Paolo Bernerdi 
Supervisore :Ch.mo Prof. Cesare Montecucco 
 
 
 
 
 
         Dottorando : Marco Pirazzini 
     
 
 
 
Table of contents 
Preface .................................................................................................................. I 
Abstract ................................................................................................................ III 
Riassunto .............................................................................................................. V 
Keywords ............................................................................................................ VII 
1. INTRODUCTION ............................................................................................ 9 
1.1 Clostridial neurotoxins ........................................................................... 11 
1.2 General considerations on CNTs ........................................................... 12 
1.3 Clinical features of botulism and tetanus ............................................... 14 
1.4 Tetanus and botulism: historical ............................................................ 16 
1.5 Synapses and neuromuscular junction: CNTs battlefield ....................... 17 
1.6 CNTs structure: intramolecular partnership ........................................... 21 
1.6.1 HC and binding ................................................................................ 22 
1.6.2 HN and translocation ........................................................................ 30 
1.6.3 L chain and protease activity ........................................................... 32 
1.7 Mechanism of action .............................................................................. 34 
1.8 nto good3  ...................................................... 38 
1.9 Aims of the thesis .................................................................................. 41 
2. RESULTS ..................................................................................................... 43 
Double anchorage to the membrane and intact inter-chain disulfide bond are 
required for the low pH induced entry of tetanus and botulinum neurotoxins into 
neurons ............................................................................................................ 45 
Time Course and Temperature Dependence of the Membrane Translocation of 
Tetanus and Botulinum Neurotoxins C and D in Neurons ............................... 61 
The thioredoxin reductase-thioredoxin system is involved in the entry of tetanus 
and botulinum neurotoxins in the cytosol of nerve terminals ........................... 69 
Botulinum Neurotoxin type A is Internalized and Translocates from Small 
Synaptic Vesicles at the Neuromuscular Junction ........................................... 77 
Botulinum neurotoxin serotype D is poorly effective in humans: an in vivo 
electrophysiological study ................................................................................ 95 
3. DISCUSSION ............................................................................................. 103 
4. REFERENCES ........................................................................................... 111 
5. Extras ......................................................................................................... 127 
5.1 Publications list .................................................................................... 129 
5.2 Congresses attended ........................................................................... 130
Preface 
th century, the 
lethal effects of some bacterial diseases were well known even in the past. 
Accordingly, ancient texts report the symptoms of some pathologic syndromes 
which are nowadays known as plague, tetanus, botulism, diphtheria, cholera or 
carbuncle. Plague became particularly notorious thanks to the description of its 
symptoms along chronicles of history but also in many and many novels or holy 
texts. Not only, the historical documentations of toxins as well as bacterial agents 
employed as weapons are also described. Often these episodes were interpreted 
as divine signs of teaching as reported in the Bible or castigation as believed 
about the death of  who consider himself as a god. 
Nowadays, it is clear that gods are foreign to such proceedings and that infective 
diseases are caused by microorganisms, namely viruses or bacteria. Anton van 
Leeuwenhoek, during the 1670s, was the first person to see bacteria thanks to a 
self assembled handcrafted microscope. He sent a report of his observation to 
the Royal Society of London with many detailed drawings but his work was 
considered with skepticism, probably because the existence of unicellular 
organisms was entirely unknown and somehow anachronistic. Therefore, in the 
next period, the knowledge that the world was crowded with small organisms was 
considered interesting but rather irrelevant. It took a long time before people 
figured out that bacteria and viruses were the cause of some diseases and were 
at the same time involved in their spreading from one person to another. Despite 
this, the idea of infectious diseases has been entertained during the 18th century 
by some enlightened people, like Antonio Vallisneri, who foresaw us 
 the proof that microorganisms not only 
exist but actively take part in life and health of people, was achieved with the 
works of Louis Pasteur and Robert Koch, even if only one century later. Their 
experiments, through which the existence of bacteria and pathogens was stated, 
represent the cornerstones of the modern microbiology and their principles are 
still used as paradigms Moreover, in 
1884, Koch had the intuition, later confirmed, that pathogenic bacteria, i.e. 
anthrax bacilli, 
them and then released into the host. In the same year, Friedrich Loeffler 
idea opened the doors to the modern concept of toxin and toxicology. Almost 100 
years later, in 1959, two independent scientists confirmed Koch hypothesis 
demonstrating that bacteria-free preparation from V. cholerae injected in animal 
models mimicked the bacterium deadly symptoms. Ten years later the causative 
agent of cholera was isolated and biochemically characterized, becoming the 
prototype of a big family of biochemically, immunologically and pharmacologically 
related toxins1. 
Starting from the observation of pioneers as Koch, Pasteur, Loeffler and many 
others, microbiology and toxicology have become two of the most important 
not only have 
contributed to human and animal health, but also have equipped modern science 
with new instruments which dissociate and analyze the most delicate 
mechanism in causing death, scientists can learn indirectly much about the 
physiological processes of life2  
The last sentence, stated by Claude Bernard in 1866, well fits with the properties 
of Clostridial Neurotoxins3 (CNTs). In a recent review, in light of the last 
discoveries, Prof. Mauricio Montal has defined these proteinaceous toxins as a 
marvel4, because of their structural architecture and intramolecular partnership 
which allow very accurate binding, penetration and eventually modification of a 
very specific process of host physiology. Exactly due to these features, such 
bacterial exotoxins are the most poisonous substances known and are therefore 
considered as potential bioweapons. On the other hand, the same properties 
have allowed a safe use for therapeutic as well as for cosmetic purposes5. 
Moreover, they are widely used by researcher as a tool to accurately manipulate 
certain physiological processes in a very specific manner, avoiding some 
drawbacks which could be generated by other kind of approach3. 
In this scenario, the study of clostridial neurotoxins not only has represented a 
great goal for human health and safety, but had also influenced the science by 
providing a very useful instrument to aliment and create new knowledge. 
Abstract 
Tetanus and botulinum neurotoxins cause neuroparalysis by inhibiting 
neuroexocytosis. They are composed by two main chains: the 100 kDa heavy 
chain (H) mediates the neurospecific binding to target cells and chaperons the 
entry of the 50 kDa light chain (L). After binding on the plasma membrane, these 
neurotoxins enter into nerve terminals via endocytosis inside synaptic vesicles, 
as shown here for the first time by immuno-electron microscopy. The lumenal 
acidic pH induces a structural change of the neurotoxin molecule that becomes 
capable of translocating its L chain into the cytosol, via a transmembrane protein-
conducting channel made by the H chain. This is the least understood step of the 
intoxication process primarily because it takes place inside vesicles within the 
cytosol. In the present study, we describe how this passage can be made 
accessible to investigation by making it to occur at the plasma membrane of 
neurons. The neurotoxin, bound to the plasma membrane of cerebellar granular 
neurons in the cold, was exposed to a low pH extracellular medium and the entry 
of the L chain was monitored by measuring its specific metalloprotease activity 
with a ratiometric method. We found that the neurotoxin has to be bound to the 
membrane via at least two anchorage sites in order for a productive low-pH 
induced structural change to take place. In addition, this process can only occur if 
the single inter-chain disulfide bond is intact. The pH dependence of the 
conformational change of tetanus neurotoxin (TeNT) and botulinum neurotoxin 
(BoNT) /B, /C and /D is similar and takes place in the same slightly acidic range, 
which comprises that present inside synaptic vesicles. Thanks to this reliable 
method we have also studied the temperature dependence and the time course 
of TeNT, BoNT/C and BoNT/D L chain entry across the plasma membrane. The 
time course of translocation of the L chain varies for the three neurotoxins, but 
remains in the range of minutes at 37 °C, whilst it takes much longer at °20 C. 
BoNT/C does not enter neurons at 20 °C. Translocation also depends on the 
dimension of the pH gradient. These data are discussed with respect to the 
contribution of the membrane translocation step to the total time to paralysis and 
to the low toxicity of these neurotoxins in cold-blood vertebrates. 
Another fundamental event along CNTs neuron intoxication process is the 
reduction of the interchain disulphide bond. This is a conditio sine qua non to free 
the catalytic part of the molecule in the cytosol of neurons. By using specific 
inhibitors of the various cytosolic protein disulfides reducing systems, we show 
here that the NADPH-Thioredoxin reductase-Thioredoxin redox system is the 
main responsible for this disulfide reduction. In addition, we indicate auranofin, as 
a possible basis for the design of novel inhibitors of these neurotoxins.  
BoNT/A is the most frequent cause of human botulism and at the same time is 
largely used in human therapy. Some evidences indicate that it enters inside 
nerve terminals via endocytosis of synaptic vesicles, though this has not been 
formally proven. The metalloprotease L chain of the neurotoxin then reaches the 
cytosol in a process driven by low pH, but the acidic compartment wherefrom it 
translocates has not been identified. Using immunoelectron microscopy, we show 
that BoNT/A does indeed enter inside synaptic vesicles and that each vesicle 
contains either one or two toxin molecules. This finding indicates that it is the 
BoNT/A protein receptor SV2, and not its polysialoganglioside receptor that 
determines the number of toxin molecules taken up by a single vesicle. In 
addition, by rapid quenching the vesicle transmembrane pH gradient, we show 
that translocation of the neurotoxin into the cytosol is a fast process. Taken 
together, these results strongly indicate that translocation of BoNT/A takes place 
from synaptic vesicles, and not from endosomal compartments, and that the 
translocation machinery is operated by one or two neurotoxin molecules. 
Another important aspect regarding CNTs research is their employment in human 
therapy. Accordingly, BoNT/A is almost invariably used in the treatment of many 
human diseases characterized by hyperactivity of peripheral cholinergic nerve 
terminals. Unfortunately, some patients are or become resistant to it. This 
drawback can be overcome by using other botulinum toxins, and pre-clinical 
studies have been performed with different toxin serotypes. Botulinum neurotoxin 
type D has never been tested in human muscles in vivo. Here we show that 
BoNT/D is very effective upon injection in mice, on the mouse hemidiaphragm 
preparation and on different rat primary neuronal cultures. From these 
experiments, doses to be injected in human volunteers were determined. The 
effect of the injection into the human Extensor Digitorum Brevis muscle was 
assayed by measuring the compound muscle action potential at different times 
after injection. Botulinum toxin type D was found to be very uneffective in 
inducing human skeletal muscle paralysis. These results are interpreted in terms 
of recent reports on neuronal surface receptors of this neurotoxin and of the 
established double receptor model of binding. 
Riassunto 
Le Neurotossine clostridiali (CNT), sono esotossine di origine batterica che 
causano le due note sindromi neuroparalitiche tetano e botulismo attraverso il 
blocco della neuroesocitosi. Sono composte da due catene principali legate 
covalentemente da un unico ponte disolfuro. La catena pesante di 100 kDa (H) 
fornisce il legame neurospecifico e media l'ingresso della catena leggera (L) di 50 
kDa nei neuroni bersaglio. Dopo il legame sulla membrana plasmatica, queste 
neurotossine entrano nei terminali nervosi all'interno di vescicole sinaptiche 
tramite endocitosi. Qui il pH acido induce un cambiamento strutturale della 
molecola che diventa capace di traslocare la catena L nel citosol, grazie ad un 
canale predisposto dalla catena H. Questo è il passaggio meno conosciuto lungo 
tutto il processo perlopiù a causa della sede dove avviene, ovvero piccoli 
studio si descrive come questo passaggio sia stato reso accessibile all'indagine 
facendolo verificare sulla superficie dei neuroni. La neurotossina, legata a freddo 
alla membrana plasmatica di neuroni primari di cervelletto, è stata esposta ad un 
mezzo tamponato a basso pH per simulare quanto avviene nelle vescicole 
sinaptiche. L'ingresso della catena L è stato monitorato misurando l'attività 
metalloproteasica specifica con un metodo raziometrico. Abbiamo trovato che la 
neurotossina deve essere necessariamente legata alla membrana con almeno 
due siti di ancoraggio al fine di andare incontro ad un cambiamento strutturale 
funzionale alla traslocazione. Inoltre, questo processo può avvenire solo se il 
disolfuro intercatena è intatto. La pH-dipendenza del riarrangiamento 
conformazionale della tossina tetanica (TeNT) e delle tossine botuliniche (BoNT) 
B, C e D è simile e avviene nello stesso intervallo, in una condizione di media 
acidità, tuttosommato simile a quella che si pensa esistere all'interno vescicole 
sinaptiche. 
Grazie a questo affidabile metodo di indagine, abbiamo proceduto studiando la 
dipendenza dalla temperatura e la cinetica della traslocazione di TeNT, BoNT/C 
e BoNT/D. A 37 °C, la traslocazione delle tre diverse tossine varia nel tempo, ma 
rimane sostanzialmente nell'intervallo di minuti minuti, mentre ne richiede molto 
più a 20 °C. BoNT/C non trasloca a 20 °C. La traslocazione, come 
precedentemente visto, dipende anche dalla dimensione del gradiente di pH. 
Questi dati vengono 
tossine per intossicare i neuroni, così come la scarsa tossicità delle tossine nei 
vertebrati a sangue freddo. 
Un altro evento fondamentale lungo il processo di intossicazione è la riduzione 
del legame disolfuro intercatena. Questa è una conditio sine qua non per liberare 
la parte catalitica della molecola nel citosol dei neuroni. Utilizzando inibitori 
specifici dei diversi sistemi ossidoreduttivi citoplasmatici, si è dimostrato che il 
sistema NADPH-tioredossina reduttasi-tioredossina, è il principale responsabile 
di questo evento. Inoltre, auranofin viene indicato come possibile molecola lead 
per la progettazione di nuovi inibitori di queste neurotossine. 
stesso tempo è indicata, quasi senza alternative, come agente terapeutico per il 
trattamento di numerose condizione patologiche. Alcune prove indicano che essa 
 dei terminali nervosi via endocitosi di vescicole sinaptiche, ma 
questo non è mai stato formalmente provato. La subunità catalitica accede quindi 
al citosol grazie ad un cambiamento conformazionale guidato da un gradient di 
pH. Tuttavia, quale sia il compartimento acido sfruttato dalla tossina per 
innescare il cambiamento conformazionale non è stato ancora determinato. 
Attraverso esperimenti di immuno detezione e miscroscopia elettronica, abbiamo 
dimostrato che BoNT/A sfrutta il riciclo di vescicole sinaptiche per essere 
internalizzata e che il numero massimo di tossine per vescicola è dettato dal 
numero di recettori proteici, 
piuttosto che dal recettore glicolipidico presente sulla membrane esterna. A 
attraverso specifici inibitori, mostra una cinetica di traslocazione di BoNT/A 
talmente rapida da poter escludere con certezza che tale evento possa avvenire 
a livello di organelli acidificabili diversi dalle vescicole sinaptiche, quali possono 
essere ad esempio gli endosomi. Presi nel loro insieme, questi risultati 
propendono per un funzionamento di BoNT/A come una nanomacchina capace 
di traslocare la subunità cat
molecole. 
Un altro aspetto per cui la ricerca sulle CNT è importante è sicuramente il loro 
impiego in terapia umana. BoNT/A è usata nel trattamento di molte malattie 
umane caratterizzate da iperattività dei terminali nervosi periferici colinergici. 
Purtroppo, alcuni pazienti sono o diventano resistenti alla terapia. Questo 
inconveniente può essere superato utilizzando altre tossine botuliniche ed infatti 
studi pre-clinici sono stati condotti con differenti sierotipi di tossina. La 
neurotossina botulinica di tipo D non è mai stato testata in vivo su muscoli umani. 
Qui viene mostrato che BoNT/D rappresenta la tossina più efficace in 
preparazioni in vivo ed ex vivo nei topi. Da questi esperimenti preliminari, sono 
state determinate le dosi da testare in volontari umani. L'effetto della iniezione nel 
muscolo delle dita umano Extensor Digitorum Brevis è stata saggiata misurando 
la risposta del potenziale  a diversi tempi dopo 
l'iniezione. BoNT/D è risultata essere scarsamente efficace nella neuroparalisi del 
muscolo scheletrico umano ed è per cui poco appetibile pe  Questi 
risultati sono stati interpretati considerando i recenti risultati in merito ai recettori 
sfruttati da tale sierotipo e il modo con cui la stessa si lega ad essi. 
Keywords 
Botulinum neurotoxins, Tetanus neurotoxin, translocation domain, interchain 
disulphide, neuromuscular junction 
 
 
  
 
 
 
 
 
 
 
 INTRODUCTION 

  
 
 
 
 
 
 
 
 
1.1  Clostridial neurotoxins  
The nervous system provides an essential function in animal physiology and 
even a minor modification within few neurons may result in a profound behavioral 
alteration. Accordingly, synaptic transmission is a key process in nervous system 
physiology where synaptic vesicles (SVs) play a major role. Many toxins act 
selectively on the nervous tissue. Interestingly, the most dangerous pathogens or 
animals, to subvert host functions at their advantage, have evolved different 
strategies aimed to impair the mechanisms involved in the neurotransmitters 
machinery. In general, neurotoxins specifically act on ion channels blocking the 
transmission of nerve impulse through the alteration of ion permeability. On the 
other hand, some bacteria of genus Clostridium have evolved an elegant as well 
as sophisticated mechanism, which affects synaptic transmission in another way. 
Such bacteria, among other, produce neurotoxins which are endowed with 
specific features aimed to accurately target nerve endings and efficiently catalyze 
the degradation of fundamental proteins within them. Such diabolic strategy 
results in the impairment of neurotransmitter release in some essential synapses, 
eventually causing two very remarkable neuroparalytic syndromes: tetanus and 
botulism. 
1.2  General considerations on CNTs 
Clostridial neurotoxins are the most poisonous substances known. One single 
isoform of TeNT is known, with an estimated human lethal dose of 2.5 ng/kg. On 
the other hand, many isoforms of BoNTs have been discovered, whose lethality 
is again supposed to be in the low nanograms per kilogram of body weight range 
(0.2 1 ng/kg). They are hundreds/thousands times more toxic than other well 
known bacterial protein killers like 
diphtheria toxin, anthrax toxin or 
cholera toxin6. Despite the very 
similar molecular and biochemical 
features of TeNT and BoNTs, which 
will be described in details in chapter 
1.6, they elicit two very different 
clinical manifestations, paradoxically 
opposite, namely a spastic and a 
flaccid paralysis respectively. Their 
extreme toxicity depends on their 
selective action toward specific 
target cells, neurons. Tetanus and 
botulinum neurotoxins indeed work 
in the same way and likewise impair 
presynaptic neurotransmission. The 
neurotransmission blockade is 
caused by the cytosolic modification 
of the machinery which governs the 
neurotransmitter release. CNTs are 
indeed zinc dependent 
metalloproteases, which specifically 
reach and hydrolyze SNARE 
proteins, a family of fundamental 
proteins that coordinates the 
regulated neurotransmitter exocytosis mechanism. This cleavage impairs the 
ability of SNAREs to bridge vesicles to the correct target membrane and 
therefore the fusion of neurotransmitter containing vesicles to the plasma 
membrane. Figure 1B-C shows the 
typical accumulation of vesicles on the 
cytosolic side of the presynaptic plasma 
membrane within the active zones 
caused by TeNT and BoNT/A 
respectively7. 
The different clinical outcomes depend 
from the different trafficking of TeNT with 
respect of BoNTs. As shown in fig 2, 
BoNTs bind and act into -motoneurons, 
thereby inhibiting acetylcholine release 
from motor nerve endings which results 
in the impossibility of muscles 
stimulation and therefore contraction 
(flaccid paralysis). 
On the other hand, also TeNT binds 
motoneurons at the neuromuscular 
junction but it is somehow hijacked in a 
protective environment8, 9, 10 till the 
cytosol of motoneurons-afferent 
inhibitory interneurons through a 
retroaxonal transport11. Here, similarly to 
BoNTs, it blocks the release of synaptic vesicles filled of GABA or glycine, 
impairing the modulation of motoneurons excitability. This results in an 
uncontrolled activity of all muscles and therefore in the spastic paralysis typical of 
tetanus syndrome. 
Even if cases of spastic paralysis had never been reported, central effects due to 
BoNTs intoxication have been recorded in many occasions, reviewed by M. 
Caleo and G.P. Schiavo in12. Consistently, BoNTs efficiently intoxicate central 
nervous system neurons in vitro13 as well as in vivo after local administration14. 
Eventually, retroaxonal transport of BoNT/A has been elegantly described in 
2008 by F. Antonucci15. 
 
1.3 Clinical features of botulism and tetanus 
Botulinum neurotoxins are produced by different neurotoxigenic strains of the 
genus Clostridium, namely C. botulinum, C. barati and C. butiricum, even if the 
largest part of botulism outbreaks is caused by C. botulinum. Seven main BoNTs 
have been identified and classified as the seven serotypes BoNT/A, /B, /C, /D, /E, 
/F and /G because antigenically distinguishable5. Recently it has been found 
hybrid serotypes between BoNT/C and /D which display a mosaic composition, 
probably originated from recombination events, presumably through a phage-
mediated mechanism. Accordingly they have been named BoNT/C-D and 
BoNT/D-C (BoNT/D South Africa). In addition to these, other botulinal toxins have 
been recently described and categorized as subserotypes. In total, more than 30 
botulinum neurotoxins isoforms are described16, 17. Serotypes A, B, E, and F are 
associated with human botulism, while few records of human intoxication are 
reported for botulinum serotype C and D18, 19, which are generally associated with 
avian or animal botulism20-22. 
C botulinum is ubiquitously present in the environment as spores. Germination 
can occur only in anaerobiosis and in a condition of low acidity (pH > 4.5). The 
intoxication is mainly caused by the ingestion of the mature toxin contained in 
contaminated food23, 24 since clostridia colonization of the intestinal tract is quite 
difficult in adults. Unfortunately, it is more likely in babies and accordingly it has 
been recently claimed as the main cause of infant botulism23, 24. Similarly to 
tetanus, botulism can be caused also by the growing and the production of 
BoNTs in anaerobic wounds (wound botulism)23, 24. Iatrogenic botulism is 
recognized as another kind of the disease and it is due to the inappropriate 
administration or the abuse of the toxin during pharmaceutical or cosmetic 
treatments.  
Despite the different serotypes, the signs and the symptoms of the disease are 
the same. The facial and throat muscles are the first affected, becoming 
progressively weak till the paralysis (figure 3). This results in diplopia, ptosis, and 
dysphagia. The paralysis continues its descent to the trunk. Autonomic nervous 
system is also involved, resulting in reduced salivation and lacrimation, nausea, 
vomiting and abdominal pain. When respiratory muscles are concerned, 
breathing is compromised and death comes through respiratory failure25. Therapy 
is aimed to neutralize circulating toxin through anti-botulinum serum and keep 
alive patients through artificial ventilation if necessary. Unfortunately, no 
countermeasures against BoNTs are available once entered in target cells, even 
if many attempts had been explored26-33. The severity of the disease is therefore 
proportional to the amount of toxins, which have intoxicated the neurons before 
antitoxin administration. Accordingly, the duration of paralysis can last for weeks 
to months20. 
The single tetanus neurotoxin is produced by Clostridium tetani. It is strictly 
anaerobe because it lacks the redox enzymes necessary to reduce oxygen and 
therefore is disseminated in the ambient as spores. It can germinate only under 
appropriate environment, where oxygen tension is low, nutrients are present and 
pH is slightly acid. The best environment in humans is therefore represented by 
necrotic tissues of skin wounds, ruptures or abrasion. Here the spore germinates 
and produce the neurotoxin which accumulates in bacterium cytosol and is 
released only after cell autolysis. Therefore it is not surprising that the first clinical 
manifestation could arise even after 20 days after skin laceration. The hallmarks 
of the syndrome are a progressive rigidity and spasticity of muscles. Generally, 
facial muscles are firstly affected. The presence of risus sardonicus (fig.3) is very 
common and due to facial muscles spasms. The classical arching of the back 
(opisthotonus) is the consequence of trunk muscles affection along disease 
progression. Spasms can be so intense to cause bones breaking or joints 
dislocation. Whether breath muscles are affected, death for asphyxiation is likely, 
unless artificial respiration is readily available. 
The medical treatment is firstly aimed to block the production of toxins, through 
antibiotics, and to neutralize any circulating toxins with appropriate serum, before 
they can enter into target cells. Whether toxins have not been neutralized in time, 
patients certainly will have the symptoms and the syndrome will be the more 
severe the more quantity of tetanus has been internalized. In such conditions, 
medical care is aimed to control muscle spasms through sedatives like 
benzodiazepines as well as to control pain. The best way to fight tetanus is for 
sure prevention, since prophylaxis is available and well tolerated. Accordingly, 
tetanus had been a major killer in the past but after the introduction of a 
systematic vaccination it is nowadays under control, at least in the developed 
countries34. In poor countries a severe and unfortunately recurrent form of the 
disease is the neonatal tetanus, generally caused by the employment of not well-
sterilized surgical instruments during the delivery. 
 
1.4  Tetanus and botulism: historical 
Neurotoxigenic Clostridia producing tetanus and botulinum neurotoxins are 
ubiquitous bacteria disseminated in the environment. Generally speaking, shoddy 
methods in food conservation, inappropriate treatment of wounds and absence of 
organized health service had been the main causes of botulism and tetanus 
outbreaks along history, which probably has accompanied mankind since its 
beginning. Accordingly, reports of tetanus clinical symptoms had been described 
in the 5th century B.C. by Hippocrates, as well as ancient dietary law and taboos 
about the risk of consuming poisonous food may reflect the knowledge of 
botulism in remote time. On the other hand, scientific studies of such diseases 
and the discovery of their relationships with Clostridia have emerged only in a 
relatively recent past. 
Carle and Rattone have described for the first time in 1884 the artificial 
transmission of spastic paralysis from a tetanized human to a rabbit and some 
years later, in 1889, Kitasato demonstrated that C. tetani spores reproducibly 
germinated under anaerobic condition and were able to reproduce tetanus in 
injected animals. The next year, he also showed that the inoculation of animals 
with small amount of purified toxin resulted in protective sera production. In 1924 
Descombey reported the development of neutralizing antibody induced by a 
chemically inactivated tetanus toxin35 (tetanus toxoid). 
The first scientific report which officially recognized botulism symptoms in 
correlation with food poisoning had been published in 1815 by a german health 
officer, Steinbuch, concurrently with a romantic poet became hereafter a medical 
officer, Kerner. The last one reported the complete description of symptoms, 
hypothesis on the etiology and pathophysiology of t s action as well as 
the primitive idea of a possible therapeutic use of it. In 1895 Van Ermengem 
isolated C. botulinum from contaminated food and collected sera from died 
victims. These samples were compared with those gotten from a subsequent 
botulism outbreak, ten years later. Leuchs found that such strains as well as 
ere different. Later in 1919 Burke, at Stanford University, 
designated them as type A and B, opening the modern area of BoNTs research35. 
Hereafter all the other serotypes were identified. In 1949, Burgen has discovered 
in London that BoNTs block the acetylcholine release at the neuromuscular 
junction. Eventually, Schiavo and Montecucco in 1992 first have demonstrated 
that BoNTs and TeNT are metalloprotease which target SNARE proteins36, 
causing the blockade of neurotransmitter release. The last discovery was the 
greatest evidence that BoNTs and TeNT, even if cause opposite clinical effect, 
are actually very similar at the molecular level. Accordingly, in the last twenty 
years, several groups has made many efforts in order to characterize in detail the 
structural and molecular details of CNTs, discovering that such toxins are indeed 
absolutely related. 
1.5  Synapses and neuromuscular junction: CNTs 
battlefield 
To better understand the reason of CNTs extraordinary toxicity, a highlight on 
synapse architecture and neuroexocytosis is needed. 
The most well characterized chemical synapse is the neuromuscular junction 
(NMJ), which is a fundamental synapse within the peripheral nervous system. 
Here, electric impulses flowing from the central nervous system are translated in 
a mechanic movement in the periphery, at the level of muscles, thereby 
permitting the locomotion. According to its fundamental role, NMJ is the target of 
BoNTs. 
The presynaptic element of NMJ is the efferent motoneuron, while the post 
synaptic element is the skeletal muscle fiber. Motoneurons are very particular 
neurons. Their soma is within the spinal cord, therefore inside the central nervous 
system, but they extend proper axons outside, reaching muscles fibers in the 
peripheral nervous system. One motoneuron generally splits its myelinated axon 
in many (20-100) non myelinated terminal fibers and each of them innervates a 
single muscle fiber, forming a motor end plate. Together, motor end plates 
belonging to a single motoneuron form the so-called motor unit, as seen in figure 
3. 
 
 
Besides NMJ, each chemical synapse contains synaptic vesicles (SVs), 
specialized cytoplasmic carriers, which store neurotransmitters, the molecules 
responsible of postsynaptic excitation. SVs are held in an actin framework in 
close proximity of the presynaptic membrane, in zones dedicated to the 
neurotransmitter release, i.e. the active zones. Upon the arrival of an action 
potential, SVs undergo to Ca2+ dependent exocytosis, after which they are 
retrieved from plasma membrane and recycled to regenerate exocytosis 
competent vesicles. Accordingly, SVs contain the machinery required for 
neurotransmitter uptake and storage, such as transporters, ion channels and the 
vesicular H+ ATPase, which provides the chemical energy to fuel the other 
proteins. Actually
are very small, 40nm, their composition is probably not fixed and can be varied 
by cytoplasmic and plasma membrane elements. In 2006, Takamori and 
colleagues tried to dissect the protein and lipid composition of SVs. Interestingly, 
among the others, they found molecules like synaptobrevins, syntaxins, SNAP25, 
SV2, synaptotagmins and gangliosides, which are directly involved in CNTs 
activity. In figure 4 is reported the molecular model of a SV37. 
 
 
SVs are moved from their actin matrix to the active zones upon action potential 
formation. Here vesicles dock and fuse with the plasma membrane to deliver the 
neurotransmitter in the synaptic cleft. Such event is promoted by a concerted 
mobilization of proteins, which 
eventually results in the 
fundamental interaction of a highly 
conserved superfamily of proteins 
known as SNAREs (Soluble NSF 
Attachment Protein Receptors). 
Such proteins are supposed to 
control recognition and fusion of 
almost all the vesicular carriers 
within the cell. Generally, two kinds 
of SNARE proteins can be distinguished: v SNAREs and t SNAREs. The first 
are present on the vesicle, which is going to fuse, while the latters are present on 
the target membrane. In SVs, SNARE parterre is composed by the v SNARE 
synaptobrevin 1/2 (also known as VAMP1/2 or Vesicle Associated Membrane 
Protein 1/2) and by the t SNAREs syntaxin 1A and SNAP25. When fusion 
occurs, these three proteins interact together thanks to a highly conserved 
cytosolic domain, known as SNARE motif. It consists in 60-70 aminoacids 
segment, which can reversibly assemble a parallel four alpha helical bundle, 
called SNARE complex. As seen in figure 6, VAMP and syntaxin 1A contribute 
with one SNARE motif, while SNAP25 zip the complex with two38. 
It is supposed that the formation of such complex releases a quantum of energy 
necessary to overcome the repulsive forces among opposed membranes and 
therefore provides the energy necessary for membrane fusion. Anyway, even if 
such phenomenon is of great interest, the detailed mechanism is still ambiguous 
and many players present either on SV and on plasma membrane are probably 
involved39. Nevertheless, what is important to consider for our purposes is that 
SNARE proteins assemble the minimal machinery compatible for fusion, 
suggesting that they are absolutely fundamental for neurotransmitter release and 
therefore in neuroexocytosis40, 41. Accordingly, it cannot be considered a 
coincidence that CNTs have evolved a strategy to specifically block 
neurotransmission by acting on SNARE proteins. 
 
1.6  CNTs structure: intramolecular partnership 
The clinical outcomes of TeNT and BoNTs are very different, almost opposite in 
their manifestations. Despite this, all CNTs intoxicate their target cells and 
produce the same intracellular modification, which is responsible for the final 
phenotype in a very similar manner. Moreover, the discovery that also BoNTs 
and not only TeNT can be retrotransported12, 15, 42, has definitely demonstrated 
that such neurotoxins are more similar than how much was thought in the past 
 flock. 
Accordingly, from the structural point of view, CNTs are absolutely related. They 
are produced by the bacteria as a single polypeptidic chain of 150 kDa which are 
subsequently cleaved by specific bacterial or host proteases into the final, active 
toxins43. As schematized in figure 3, the mature toxins are composed of two main 
chains, linked by a unique disulphide bond. 
 
 
The smaller chain, 50 kDa, called light chain (L), is the catalytic part of the toxin 
and is responsible for the protease activity toward SNARE proteins. The bigger 
chain, 100 kDa, is called heavy chain (H) and can be functionally divided in two 
subdomains. The amino-terminal part (HN, 50 kDa), also known as translocation 
domain, in response to low pH, inserts inside membrane and forms cation- 
selective channels44-47 and has been ascribed to the L chain delivery from the 
uptake compartment to the cytoplasm, across an intracellular membrane4, 48-50. 
The 50 kDa carboxy-terminal part (HC) is responsible for the specific binding to 
motoneurons plasma membrane43. 
The molecule can be considered as a nanomachine4. The crystal structures of 
BoNT/A, BoNT/B and BoNT/E reveal that the structure is modular51. Each part 
interplay with the others, resulting in a wonderful example of intramolecular 
partnership4. The intoxication process consists of 4 main steps24, 52: (1) the 
neurospecific binding, (2) the cytosolic internalization, (3) the membrane 
translocation and eventually (4) the SNARE degradation. Another fundamental 
event, which can be considered as an extra step, is the disulphide reduction of 
the interchain disulphide bridge, necessary in order to free the L chain into the 
cytoplasm. Besides the very similar tridimensional structure and functional 
organization, which result in a very similar intoxication mechanism, each 
neurotoxin maintains proper features, which make them reciprocally unique. 
These differences are mainly evident in some properties, such as binding 
modalities and target specificity, which will be described in the next sections. 
1.6.1 HC and binding 
As previously said, the HC is responsible and sufficient for the neurospecific 
binding at the neuromuscular junction53-57. As depicted in figure 7, it can be 
structurally subdivided into two parts, the 25 kDa C-terminal one (HCC) and the 25 
kDa N-terminal one (HCN). 
HCN is a lectin like domain, highly conserved among CNTs, with a jelly role motif 
similar to that of carbohydrate binding protein (legume lectins). Actually, no 
carbohydrates binding properties have been reported in this domain and its 
function remains therefore still elusive. It has been reported its ability to bind 
phosphatidylinositols and phosphoinositides, at least for BoNT/A and BoNT/C. it 
has been proposed that such interaction could assist the correct positioning of 
HN for the membrane insertion58, 59. 
Nevertheless, it is HCC that harbors the fundamental features for the specific 
binding to motoneurons as well as for the different trafficking of TeNT with 
respect to BoNTs43. 
HCC -trefoil domain and its selectivity for neuronal membranes is one of the 
hallmarks, which makes CNTs the most poisonous toxins known. Accordingly, 
along the last 15 years, the structural and molecular details on the binding 
strategy of each toxin had been investigated. 
Many groups have identified gangliosides as critical molecules for the specific 
binding to neuronal cells, reviewed by Binz and Rummel43. Gangliosides are a 
large family of glycolipids (glycosphingolipids) present on the external plasma 
membrane of all animal cells which are involved in many pathways like cell 
signaling, cell adhesion, protein sorting and are very important for membrane 
domain formation, existence and organization60. Neurons are particularly 
enriched in gangliosides, especially in axons and dendrites where they govern 
membrane curvature. The molecule is based on a ceramide-oligosaccharide 
framework modified with one or more sialic acids (monosialogangliosides and 
polysialogangliosides respectively) (PSG). Figure 8 shows an example of such 
molecules61. 
 
Many attempts have been explored to demonstrate the role of gangliosides in 
CNTs toxicity. TeNT and many BoNTs show high affinity toward PSG 
immobilized on a solid substrate. Furthermore, removal of sialic acid residues 
with neuraminidase decreases BoNT/A and TeNT potency in spinal cord 
neurons62, while insensitive chromaffine cells become sensitive to TeNT and 
BoNT/A by preventive decoration with gangliosides mixture63-65. 
  
Accordingly, the inhibition of gangliosides biosynthetic chain (figure 9) in primary 
spinal cord neurons or in neuroblastoma cell line confers resistance to TeNT and 
BoNT/A respectively67, 68. Moreover, genetic ablation of NAcGal-tranferase, which 
blocks the biosynthetic pathway and limits gangliosides expression to GM3, GD3 
or their precursor, reduces binding and entry of BoNT/A, /B, /E and /G in 
hippocampal neurons which can be restored by adding exogenous 
gangliosides69, 70. The same genetic ablation blocks TeNT and decreases 
BoNT/A and BoNT/B toxicity in vivo71, 72.Similarly, mice expressing only Lac-Cer, 
GM3, GM2, GM1 and GD1 because GD3-synthase ablated, are TeNT resistant, 
but BoNT/A, /B, /E sensitive73. Knocking out both genes, double knock out mice, 
which can express only GM3 ganglioside, display resistance to BoNT/B and /G74, 
while GM3 synthase knock out mice, which can express Lac-Cer solely, are 
refractory to BoNT/C75. It is therefore clear that complex gangliosides such as 
GD1a, GD1b and GT1b are fundamental components, which mediate the 
anchorage of CNT to neuronal membranes. 
The interaction between CNTs and gangliosides at the molecular level has been 
extensively studied. Co-crystallization experiments of TeNT HCC with GT1b have 
shown two main interaction sites. In one a lactose moiety interacts with the 
residues D1222, T1270, S1287, W1289, Y1290 and G1300, while in a second 
one a sialic acid interact with R122676. In these interactions, W1289 and R1226 
play a pivotal role for TeNT anchorage77, and therefore these two sites had been 
named the W lactose (lactose binding pocket) and the R sialic site (sialic binding 
pocket)78. Chen and colleagues resolved the anchorage properties of each 
binding sites through solid phase binding assays. It was reported that the sialic 
site preferentially binds b series gangliosides, while the lactose binding site 
preferentially binds a series gangliosides79. Figure 10 schematically summarizes 
such interaction. It can be therefore concluded that gangliosides are necessary 
and sufficient for TeNT binding78. 
 
 
The lactose site in TeNT is composed by the sequence H...SXWY, which is 
typical for carbohydrate engagement sites and is found also in other bacterial 
toxins like ricin and cholera. In this kind of pocket, histidines imidazole ring and 
tryptophan indole ring are perpendicular to each other, while the tyrosine and 
serine form the backwall of the pocket. The interaction is generally supported by 
the aromatic residue which supplies a hydrophobic and planar surface where the 
ganglioside sugar ring can stack, while the polar residues interact with sugar 
hydroxyl groups, as shown in figure 11. 
 BoNT/A, /B, /E, /F and /G share with TeNT the conserved lactose H...SXWY (in 
BoNT/G H is replaced with G and in BoNT/E H is replaced with K) and therefore, 
similarly to TeNT, they bind PSG oligosaccharide portion such as GD1b or 
GT1b43. Accordingly, Swaminathan and Eswaramoorthy have shown that BoNT/B 
interacts with carbohydrates through the lactose binding site80, 81. Interestingly, 
while mass spectrometry analysis with TeNT HCC shows the retention of two 
carbohydrate molecules77, the same experiment with BoNT/A and BoNT/B HCC 
displays the retention of only one carbohydrate molecule82. Accordingly, because 
they bind only one gangliosides, the lactose binding site is called the gangliosides 
binding pocket (GBP). In figure 7 is 
reported the GBP of BoNT/A. On the 
other hand, the sialic binding pocket 
within such serotypes is not 
conserved at all. Actually, the fact 
that neurons stimulation increases 
the uptake and the entry of BoNT/A83-
85, has raised the possibility that 
BoNTs could interact with another 
partner which induces their entry 
through the endocytic compartment. Because stimulation of neurons increases 
exo/endocytosis events, and particularly the recycling of synaptic vesicles, the 
binding to the luminal domain of a SV protein, which is temporarily exposed to the 
 
outside and therefore available for the interaction, had been considered a very 
exciting option as well as the most likely explanation43. 
Montecucco first proposed that BoNTs extraordinary potency could derive from 
their ability to bind neurons via two receptors, one with low affinity, the 
gangliosides, which increases toxin density on target membrane, and a 
secondary one which triggers the internalization through the endocytic 
compartment86. Classical biochemical approaches lead to the discovery of 
BoNT/B interaction with synaptotagmin I and II87, 88. Subsequent studies provided 
by Dong and colleagues finally proved, through elegant loss/gain of function 
experiments, that BoNT/B binds gangliosides as low affinity receptor and exploits 
the interaction with synaptotagmin I/II for the internalization89, experimentally 
demonstrating  double receptor concept. A little later, it was shown 
that also BoNT/G could interact with synaptotagmin I/II in vitro90. This was 
confirmed some years later by biochemical experiments on neuronal culture as 
well as in vivo69. In 2006 Chai and Jin, together with their respective research 
groups, independently resolved the co-crystal structure of BoNT/B with 
synaptotagmin II91, 92. From the crystals, it has been understood that BoNT/B 
interacts with a string of 20 aminoacids within the N-terminal domain of 
synaptotagmin II (44 66), which is the luminal part of this protein, fundamental 
during SV exocytosis events. Such string is normally devoid of secondary 
structure, but assumes an helical structure upon interaction with a cleft in BoNT/B 
binding domain, located in proximity of the gangliosides pocket as shown in figure 
13. 
 
In 2007, Rummel and colleagues demonstrated through computer assisted 
analysis that, the same cleft within the binding domain of BoNT/G, interacts with 
the same synaptotagmin I/II aminoacids string74. BoNT/B and /G HCC show a 
good degree of conservation43, which is not shared by and among the other 
serotypes. Accordingly, t bind synaptotagmins. However, the 
discovery of BoNT/B proteinacious partner prompted the research in this 
direction. Accordingly, with similar approaches employed for BoNT/B, the protein 
receptors of other BoNTs have been rapidly identified. Immunoprecipitation, pull-
down and competition experiments lead to the discovery of synaptic vesicle 
protein 2 (SV2) as the protein receptor of BoNT/A93, BoNT/E70 and BoNT/F94. 
Interestingly very recent studies revealed that BoNT/C and BoNT/D, differently 
from other BoNTs, bind neurons via two gangliosides, as TeNT does, but with 
different modalities. One binding site is located in the same position where 
BoNTs interacts with their protein partner95, 96. In BoNT/D the structural shape of 
the pocket is very similar to the sialic acid binding site of TeNT95. The other 
binding site is in a position related to the GBP of BoNT/A, /B, /E, /F and /G. The 
peptidic motif responsible of the interaction, similar among these neurotoxins, in 
BoNT/C is only partially conserved and in BoNT/D 
this, from the structural point of view the architecture of the pockets is maintained 
and therefore contribute for ganglioside accomodation95, even if with peculiar 
modality. Figure 14a and b show the gangliosides binding sites within BoNT/D 
and BoNT/C HCC respectively. 
 
 
Moreover, it has been reported that BoNT/C, /D and /D-SA have an extra site of 
interaction with gangliosides, in a position which is close to the GBP in other 
BoNTs97, 98. In BoNT/C, /D and /D-SA, from the structural point of view, this site is 
-hairpin loop. Accordingly, it has been called gangliosides binding loop (GBL)99. 
This region is actually present also in BoNT/A and BoNT/B but it count for 
gangliosides interaction, probably because, differently from BoNT/C and /D-SA 
HCC, they lack a fundamental tryptophan (W1258 and W1252 respectively) which 
interacts with the ganglioside. Actually, also BoNT/D has a tryptophan (W1238) in 
the GBL, but it seems to be not essential for the interaction, which is mainly 
mediated by two phenylalanine residues (F124097 and F124295). Figure 15 shows 
the architecture of BoNT/C, /D and D-SA GBL with respect to BoNT/A and /B, 
highlighting the aminoacids fundamental for ganglioside interaction. Solid phase 
immobilization of different gangliosides, demonstrated that BoNT/C and 
BoNT/D97 preferentially bind b series gangliosides, such as GD1b and GT1b, 
while BoNT/D-SA is unique among CNTs because prefers GM1a99. 
 
 
Therefore it is possible summarize the binding properties of CNTs saying that 
TeNT, BoNT/C and BoNT/D bind to different kinds of ganglioside which are 
present on the external leaflet of neuronal cells, while other BoNTs, including 
BoNT/A and BoNT/B exploit at first a low affinity interaction with gangliosides, 
but, to properly complete their binding, they need the support of the luminal 
domain of a SV protein, i.e. SV2 and synaptotagmin I/II, respectively. 
1.6.2 HN and translocation 
The N-terminal domain of the 
heavy chain (HN) is a fundamental 
part of CNTs. It is supposed to 
mediate the translocation of the 
catalytic part from the 
endocytosed vesicle inside the 
cytosol in order to reach SNARE 
substrates. It is a 50 kDa 
polypeptide, corresponding to 
segment 685-827 in BoNT/A 
primary structure, with an 
elongated shape designed by two 
long and parallel helices51, 80. In addition to them, the HN domain also consists 
of a random coil aminoacids string, called belt region that wraps around and 
partially shield the active site of the L. From the crystal structure of BoNT/A and 
BoNT/B it is possible to note that HN confers, together with the other two 
domains, the characteristic butterfly shape to the toxins, as seen in figure 16. The 
translocation domain shows high degree of conservation among serotypes with 
exception of the belt4. HN is similar to the configuration of some viral proteins 
which responds to acidification by changing their conformation100, 101. 
Accordingly, CNTs exploit the pH gradient, generated by the vacuolar proton 
pump, to change its molecular structure. This results in the insertion of the 
translocation domain inside the membrane, with the formation of a 
transmembrane protein conducting channel4. Channel formation and membrane 
translocation of CNTs have been studied with liposomes and planar lipid 
bilayers44-48, 102. Montal and Koriazova elegantly demonstrated that, upon 
acidification, BoNT/A was able to translocate across a planar lipid bilayer the 
catalytic subunit, with the formation of an ion conducting channel48. A more direct 
approach, using cell membranes patch clamping recordings, has been explored 
by many groups103, 104. Moreover Fisher and colleagues, with a similar strategy, 
demonstrated that BoNT/A heavy chain acts as a chaperone to maintain unfolded 
the light chain during membrane translocation and predispose the reduction of 
 
the interchains disulphide bridge4, 50, 105. Interestingly, such approach 
demonstrates L chain membrane bypass through the progressive channel 
activity. Before acidification, current conductance is absent, then, lowering pH, 
ions leakage starts partially, because the channel is occluded by L transit. 
Eventually, it enters in an ion-conducting state as L is translocated (figure 17). 
Even though such procedure is reliable and prone to external manipulation, one 
limitation is the lack of information about the efficiency of membrane 
translocation, because these approaches mainly analyze single channel events. 
Furthermore, no information about the modality through which translocation 
domain approaches the membrane can be deducted. 
 
 
From the crystal structure of BoNT/B bound to ganglioside and synaptotagmin II, 
two main hypotheses have been made about HN positioning with respect to the 
other parts of the toxin and the membrane. Chai et al. proposed that HN helices 
stay with a parallel orientation with respect to the membrane, facilitating their 
interplay91 by placing hydrophobic segments in proximity to the vesicle 
membrane surface, (figure 18a). On the other hand, Jin and colleagues have 
suggested that HN helices sit orthogonal to the plane of the membrane, as 
depicted in figure 18b92. 
 Translocation step remains the less understood process and little is known 
concerning the aminoacids, which regulate the conformational change of HN for 
membrane insertion. Accordingly, understanding how translocation domain is 
positioned with respect to the plasma membrane is a question of major interest 
because could share light on the intramolecular events necessary for channel 
formation. 
1.6.3 L chain and protease activity 
Light chain is the catalytically active part of CNTs which is responsible for 
cytosolic hydrolysis of SNARE proteins and therefore of the blockade of 
neurotransmitter release. The crystal structures of all CNTs L chains have been 
determined at atomic resolution. They share a very similar tridimensional 
structure, which is similar to that of zinc dependent metalloprotease thermolysin. 
Even if they are very similar in structural organization each L have a unique 
SNARE specificity. Accordingly, as seen in figure 6, L/B, L/D, L/F, L/G and 
L/TeNT hydrolyze synaptobrevin 2 (VAMP2), L/A and L/E hydrolyze SNAP25, 
while L/C is unique and acts either on SNAP25 and syntaxin4, 106, 107. 
They all belong to zinc metalloprotease family but are endowed with a unique 
structure among them. The active site is related to that of thermolysin and has a 
core of aminoacids, conserved among CNTs108 (peptide motif HEXXH, figure 7 
and 19), which is essential for catalysis because it coordinates a catalytic zinc. 
  
Accordingly, the zinc is bound to such motif thanks to a glutamic acid and the 
imidazole rings of the histidines. A fourth coordination point is provided by a 
water molecule, bound to the glutamic acid107 (figure 20). Due to its interaction 
with the catalytic water, the E residue is particularly important, indeed its mutation 
leads to complete loss of protease activity109. In addition to the catalytic core, 
there is a secondary layer of residues, less close to the zinc center, including 
Arg362 and Tyr365 (numbering of BoNT/A), which seems to be directly involved 
in the hydrolysis of the substrate110-113. 
 
 
As seen in figure 16, L is -h -strand. The 
active site is located in a buried cleft where substrate can access along a groove 
in order to complementary fit for the processing, as depicted in figure 21. 
Interestingly, such groove can be occupied also by the belt region, suggesting 
that perhaps such structure could work as a false substrate to inhibit protease 
activity till the L is released in the cytosol through the reduction of the disulphide 
bridge114. Moreover, the crystallization of L in complex with its substrates has 
provided practical evidence of an array 
of substrate-binding sites remote from 
the active site (so-called exosites)115, 116. 
A major role is played by a string of 9 
aminoacids within the SNARE 
substrate. The motif is featured by the 
alternation of three acid aminoacids with 
hydrophobic and hydrophilic residues116-
119. There are two copies of such motif 
in synaptobrevin and syntaxin, while 
there are four in SNAP25. Such 
exosites are fundamental for CNTs 
cleavage and accordingly the presence 
of at least one copy is a stringent 
condition for toxins catalytic activity. 
Accordingly, the high specificity for the 
substrates is mainly due to such 
interactions rather than active site 
architecture. 
1.7 Mechanism of action 
As said before, CNTs have a multi-modular architecture, which is functional to 
their mechanism of action. CNTs exert their neurotoxic effect through an 
intramolecular partnership among their different domains, which results in a 
multistep mechanism24, 52: binding, internalization, intracellular trafficking, 
membrane translocation and eventually proteolytic degradation of SNAREs. 
Figure 22 summarizes such main steps. 
It is important to underline that what determines the CNTs trafficking inside nerve 
endings is the HCC. As discussed above, CNTs have unique binding properties, 
which mediate their intracellular fate. The current accepted model, which 
describes CNTs binding and internalization, is the double receptor model. It 
consists in the idea that CNTs initially bind a molecule present on the 
extracellular leaflet of the plasma membrane and, only subsequently, interact with 
 
another partner, possibly a protein, which mediates their penetration inside target 
neurons4, 43, 120. Accordingly, it has been proposed that the low affinity interaction 
with polysialogangliosides provides the accumulation of CNTs on peripheral 
neurons. Hereafter, the destiny of BoNTs and TeNT somehow diverges. Some 
BoNTs bind the luminal portion of a SV protein, strongly supporting the idea that 
they penetrate inside neurons via endocytosis of synaptic vesicles, though this 
has not been formally proven. Different groups have reported convincing 
evidences about BoNT/A, /E and /F binding to SV270, 93, 121-123 as well as BoNT/B 
and /G binding to synaptotagmins I/II69, 74, 87, 88, which are SV proteins with a 
luminal portion. 
The protein receptor of the other BoNT serotypes has not been conclusively 
determined. Recently, it has been proposed that BoNT/D and BoNT/D-C are 
internalized in central nervous system neurons thanks to SV2 and synaptotagmin 
I/II interaction, respectively124, 125. In agreement with what said before, it seems 
that BoNT/C binds neurons only through gangliosides interaction. Moreover, 
many attempts have been explored in order to identify a potential proteic partner 
but they have failed. Therefore, it could be that such toxin does
recycling to enter into target cells. Nevertheless, stimulation of cultured neurons, 
which increases SV recycling, enhances its internalization. Thus, to date it seems 
that SV recycling helps BoNT/C entry, but it is not clear whether gangliosides 
alone are sufficient to mediate its internalization126. 
Similarly to BoNTs, TeNT binds polysialogangliosides at peripheral nerve 
terminals. Nevertheless, its translocation in peripheral neurons cytoplasm is 
somehow blocked and the internalization vesicle hijacked into a retroaxonal 
pathway8-11. Great efforts have been made in order to understand the modalities 
of such event. Deinhardt and colleagues have made one major discovery by 
demonstrating that, at the periphery, TeNT is not internalized in SV as BoNTs, 
but it is present into clathrin coated vesicles. Such sorting might be due to 
glycol protein carbohydrates which undermine GD1b or other b-series 
gangliosides which have provided TeNT initial binding through the carbohydrate-
binding pockets127. Accordingly, TeNT HCC has been reported to interact with a 
GPI-anchored glycoprotein and to bind to lipid rafts52, 57, 128, 129. Therefore, TeNT 
would exploit the same trafficking of neurotrophins, like BDNF and NGF, in order 
to be retrotransported from the peripheral nervous system to the central nervous 
system8, where eventually it penetrates inside the cytosol of inhibitory 
interneurons. 
 
Therefore, TeNT HCC can be intended as a nice tool to track in vivo retroaxonal 
transport as well as an efficient system to deliver cargos to the central nervous 
system, bypassing the blood brain barrier9. To prevent the translocation of the L, 
the vesicle where TeNT is internalized in nerve endings, displays a protected 
environment with a controlled pH10. Recently, it has been proposed by Yeh and 
colleagues that, once arrived close to target neurons, also TeNT could exploit the 
interaction with a SV protein, i.e. SV2 as BoNT/A, /E and /F do, to be internalized 
in a compartment compatible with the translocation of the L chain in the 
cytosol130. On the other hand, Blum and colleagues demonstrated that TeNT can 
enter into stimulated and non-stimulated neurons at the same extent. This 
suggests that the need of synaptic vesicles recycling as well as the presence of a 
proteic receptor could be not essential for tetanus entry into central nervous 
system neurons. 
Recently, as aforementioned, it has been demonstrated that also some BoNTs 
may undergo to retroaxonal transport. 
Once internalized in the final neuronal target, the CNT-receptor complex is 
exposed to an acidic milieu provided by the vesicular proton pump v-ATPase, 
which acidifies SV in order to create a pH gradient necessary for neurotransmitter 
refilling. Such acid environment induces a conformational change on toxins 
structure, leading to the insertion of the HN, into the endosomal membrane24, 131, 
132, thereby forming a transmembrane protein-conducting channel that delivers 
the L into the cytosol where it acts4, 105, 107. Indirect evidence for the need of 
acidification along translocation is the fact that some drugs, which prevent 
vesicles acidification by v-ATPase specific inhibition, block CNTs entry and 
toxicity85, 133. Similarly, buffering the vesicular lumen with chemicals, the L cannot 
translocate and remains entrapped inside vesicle134. The low pH-driven toxin 
conformational change has been reported to take place in a very narrow range of 
pH: 4.4 4.6 for TeNT, BoNT/A, /B, /C, /E, and /F132. Unfortunately such 
experiments have been made with artificial membranes, which lack the 
complexity of a biological membrane. Nevertheless, what remains interesting is 
that all CNTs behave similarly in response to pH drop, suggesting that perhaps 
key residues involved could be conserved. 
The diameter of the channel provided by the HN is estimated to be around 15 Å. 
Given that the folded L exceeds such dimension, it must undergo to an unfolding 
process in order to pass through the channel. Circular dicroism and 
crystallographic evidences135, demonstrate that the L 
change significantly, rather, the tridimensional shape passes from a globular 
configuration to a more elongated shape, suitable for channel transit. This has 
been proved by following the exposition of hydrophobic residues within L 
structure, as shown in figure 23136. 
 
 
After translocation, the interchain disulphide must be reduced and the L chain 
refolded before reaching and processing its substrates. The catalytic activity is in 
fact achieved only after disulphide reduction, which is a conditio sine qua non that 
precludes toxin functionality. To date no one has understood either which is the 
cytosolic reducing agent or whether L is able to refold alone or needs the 
assistance of cytoplasmic proteins. However, once free in the cytosol, the 
cleavage of the SNAREs can eventually occur. The hydrolysis of one single kind 
of SNARE protein is sufficient for vesicle fusion abrogation, which thereby causes 
the severe paralysis pathognomonic of botulism or tetanus4. 
1.8 CNTs 3  
As shown in figure 1, the most evident consequence of CNTs intoxication is the 
accumulation of SVs on the cytosolic face of the plasma membrane7. However, 
from the morphological and anatomical point of view, intoxicated neurons 
result damaged137, 138. Anatomically, contacts between muscles and nerves are 
completely maintained. On the other hand, the number of motor end plates on 
single muscle fibers and the number of fibers innervated by a single motor axon 
reciprocally increases, probably because, to prevent muscles atrophy and restore 
the NMJ functionality, muscle cells release trophic factors. This results in similar 
alterations documented in other form of denervation. However, during a 
secondary late phase of NMJ recovery, newly synthetized elements degenerate 
and the original endplate recovers completely its functionality. The time of 
recovery can vary depending on the type of nerve terminal, the BoNT serotype, 
the animal species and its dosage. 
Given that the paralyses of muscles is followed by a full functional recovery 
devoid of major alteration of the system, the employment of CNTs, especially of 
BoNTs, has found fertile ground as therapeutics for the treatment of a variety of 
human diseases. The first toxin used for human therapy was BoNT/A, approved 
by US Food and Drug Administration in 1989. It has been employed for the 
treatment of strabismus, blepharospasm and hemifacial spasm. From that day, 
the number of indications that can be treated with BoNTs has considerably 
increased. To date many human diseases, characterized by hyperactivity of 
peripheral cholinergic nerve terminals, as focal dystonias, spasticity, tremors, 
hyperhidrosis, migraine and tension headaches, but also cosmetic application are 
indicated for BoNT/A treatment139. Next studies, which have compared the 
duration of many serotypes, demonstrated that BoNT/A has the longer effect, 
whereas BoNT/B has a similar duration of action only when used at higher 
dosage. BoNT/F and BoNT/E have the shortest effect140, 141. BoNT/C has been 
reported to have a span comparable to BoNT/A142. The investigation of non A, 
non B BoNTs efficacy for human purposes is a very important issue from the 
therapeutic point of view. Indeed, over many years of clinical recording, the 
usage of BoNT/A has shown the existence of non responding subjects as well as 
the drop of efficacy due to antibodies development. To date, unfortunately, few is 
known about the employment of other serotypes, such as BoNT/D or other 
mosaic toxins composed by recombination between BoNT/D and BoNT/C which 
could represent a reservoir for potential therapeutic employment. Table 1 shows 
a list of the main diseases treated with BoNTs. 

1.9 Aims of the thesis 
The translocation step remains the less understood event along CNTs neuron 
intoxication mechanism. Available informations indicate that such process is 
driven by a transmembrane pH gradient inside vesicles4, 48, 132. Most studies were 
performed with model membrane systems48, 132, whilst in vivo experiments used 
as read out an indirect electrophysiological measurement. Even though such 
approaches have shared light on several molecular features of the translocation, 
no information on the efficiency can be inferred, because they report single 
molecules behaviors. During my PhD, I developed an assay that couples 
translocation event with its direct effect into neurons cytoplasm, i.e. SNAREs 
hydrolysis. Conditions that by-pass the SV endocytosis step and induce the entry 
of the L chain directly from the plasma membrane were found using primary 
cultures of cerebellar granular neurons (CGNs), which are almost exclusively 
composed of neurons, and the pheochromocytoma cell line PC12. The protocol 
consists in: a) binding of the toxin in the cold in order to avoid the canonical 
internalization, b) rapid change of culture medium pH at different T to induce the 
translocation of the toxins across the plasma membrane and, c) overnight 
incubation in normal culture conditions to allow SNARE cleavage. This last step 
is performed in the presence of bafilomycin A1 to block cell entry of those 
molecules, which have not translocated across plasma membrane and can 
therefore intoxicate cells via the canonic route. 
The protocol was reliable and has allowed us to study, in addition to the already 
known pH dependence, the time and the temperature dependence of the 
translocation, two parameters which strongly influence biological processes. 
Moreover, nothing was known about the cytosolic reducing system which can 
free the L chain after translocation. This is another fundamental event along 
CNTs entry mechanism and interfering with it could be an interesting strategy to 
stop intoxication, since the reduction is a conditio sine qua non for L protease 
activity. There are several disulphide bond reducing systems in the cytosol of 
cells and I have used a pharmacological approach to identify which of them is 
involved in the reduction of the interchain SS bond of TeNT and BoNTs. The 
major protein disulfide reducing systems, in addition to the glutathione pool, are 
the NADPH-thioredoxin reductase-thioredoxin system and the glutathione-
glutaredoxin system. They are implicated in controlling a variety of cell functions 
altered in a number of human diseases. Accordingly a large number of drugs 
have been developed to be evaluated as candidate drugs for clinical use and we 
used specific one to test the role of the various systems.  
The internalization step, as well as the trafficking of CNTs inside peripheral nerve 
endings, is the subject of many studies because toxins tropism represents a 
potential issue either for the formulation of antitoxins or for the development of 
neurotoxin based molecular probes. Additionally, it could be useful also in order 
to shed light on another fundamental issue, i.e. the possible cooperation between 
many toxin molecules for a productive translocation of the catalytic moiety. In this 
scenario, the study of BoNT/A is of major interest because this neurotoxin is 
responsible for the greatest part of human botulism cases and is almost 
invariably used in human therapy. 
Some evidence support the idea that BoNT/A enters via synaptic vesicles, but the 
actual presence of toxins inside vesicles, and the type of vesicles through which 
the translocation occurs, has not yet been determined. Here, the entry of BoNT/A 
into the nerve terminal of the mouse NMJ was studied by using a BoNT/A HC-
EGFP chimera and fluorescence microscopy and immunoelectron microscopy 
with gold-labeled anti-GFP antibodies. Moreover, experiments aimed to quench 
the pH of endocytic compartments at different time points were performed in 
order to identify the subcellular compartment where BoNT/A translocation takes 
place. 
Another fundamental aspect concerning CNTs study is their employment in the 
treatment of human diseases. Even if BoNT/A is the most used as therapeutics, 
its application is sometime hampered by intrinsic patients resistance or the 
development of antitoxin antibodies. In the last years, other serotypes have been 
investigated for their efficiency in humans142, 146-148. However, BoNT/D was never 
tested in human muscles in vivo. BoNT/D could be a very interesting alternative 
to other BoNTs because it is the most potent serotype in mice and therefore it 
could be used in very little amount limiting antiserum development. Here we 
compared BoNT/D potency in mice and Extensor Digitorum Brevis muscles of 
human volunteers.  
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Membrane translocation is the less understood event along CNTs intoxication 
process. Actually, it is very hard to study such event because it takes place inside 
endocytic compartments of neurons which are poorly amenable to manipulation. 
We therefore decided to avoid this limitation by making the process occur at the 
plasma membrane level, taking example from an experiment first performed with 
diphtheria toxin143-145. This assay permits a tight control of translocation 
environment which can directly influence toxins behavior. We firstly attempted 
with BoNT/A and BoNT/B, because they are the most investigated and are used 
in therapy. Unfortunately, the experiment performed with them clearly shows the 
lack of translocation, but, interestingly, TeNT, BoNT/C and BoNT/D displayed the 
ability to translocate across the plasma membrane. Given that CNTs are very 
conserved from the structural point of view but maintain proper features which 
make them unique, we ascribed such difference to the diverse binding modalities. 
It has been discussed above that BoNT/A and BoNT/B interact with only one 
exposed molecules on neuronal membranes, while TeNT, BoNT/C and BoNT/D 
have at least two anchorage point. We therefore speculated that, once bound, 
CNTs must limit their rotational degrees of freedom in order to properly 
predispose the structural rearrangement for translocation. Accordingly, providing 
BoNT/B secondary binding partner on the plasma membrane, it recovers the 
ability to translocate in our experimental conditions. This is an interesting result 
because it extends the double receptor concept to the low pH induced membrane 
insertion and translocation of the L chain and demonstrates that, providing the 
correct binding configuration, CNTs can be inserted also into cells which normally 
are refractory. This in turn gives the possibility to use CNTs as an interesting tool 
to study the role of SNARE proteins in secretion in non neuronal cells. 
Interestingly, all the toxins tested have similar pH dependence for the induced 
membrane translocation. This suggests that the machinery which governs 
translocation is probably maintained among different serotypes. Accordingly, a 
bioinformatic analysis has shown that a pool of aminoacids is strategically 
conserved in one face of the translocation domain. Interestingly, they are acid 
residues. Their properties can therefore compensate for histidines absence on 
the toxin solvent interface, other feature shared among CNTs, and provides a 
mode to the toxins to sense pH variation. 
More importantly, we found that our low pH induced translocation assay is a 
reliable method to study other parameters which generally influence molecular 
dynamics. Accordingly, we adjusted our protocol by changing the time and the 
temperature along the low pH period. The main general result was that, at 37 °C, 
translocation is very rapid for BoNT/C, BoNT/D and TeNT and is completed 
within minutes. On the other hand we also found that temperature strongly affects 
the translocation. BoNT/C is completely blocked at 28 °C. It is possible that this 
toxin is the result of an evolution that has led to the long known higher resistance 
of BoNT/C to temperature. Accordingly, this could be correlated with the fact that 
these serotypes mainly affects birds, which have a higher body temperature. 
Similarly, the finding that TeNT action is very limited when translocation is 
induced at 20 °C, fits very well with the low sensitivity of cold-blood animals such 
as amphibians and reptiles to tetanus. BoNT/D seems to be less sensitive to 
temperature decrease. 
At the same time, our assay has shed light on the importance of interchain 
disulphide. Some evidences had already demonstrated that disulphide was 
important for CNTs toxicity149-153, but it was not known which of the four main 
steps was affected. Here it has been shown that the disulphide is fundamental for 
the structural rearrangement and it is possible to speculate that probably it 
provides a third anchorage point in the membrane to help HN insertion during pH 
drop. 
Besides its role along translocation, when L has passed the vesicular membrane, 
the disulphide must be reduced to allow the release from a membrane bound 
compartment into the cytosol. To date little is known about such event and it has 
been poorly investigated. Interestingly, given its importance, it could be 
considered as a new target to block CNTs entry in neurons. We decided to 
exploits the vast knowledge available about cytosolic reducing system and 
focused our investigation on the main two: the glutathione pool and the NADPH-
thioredoxin reductase-thioredoxin system. Employing a pharmacological 
approach we found that thioredoxin reductase is involved in CNTs entry into 
neurons because its inhibition results in the block of TeNT, BoNT/B, BoNT/C and 
BoNT/D toxicity. Given that thioredoxin reductase in not directly involved in 
disulphide reduction/isomerization of cytosolic proteins, we guess that the directly 
involved reducing agent is thioredoxin. Interestingly, it has been reported that 
thioredoxin shares structural similarities with group-I and group-II chaperons154, 
155 and indeed thioredoxin can help the folding of proteins in redox-independent 
reactions156, 157. Thus, it is tempting to speculate that the thioredoxin system not 
only detaches the L chain from the HN domain, but also assists the refolding of 
the L chain which must necessary unfold in order to pass through the HN 
transmembrane channel. It remains unclear whether thioredoxin alone can 
accomplish such process or specialized chaperon proteins rather must assist it. 
Interestingly a well documented system of SV chaperons assists SNARE proteins 
folding turnover necessary for SNARE complex assembly and disassembly158, 159. 
Here it has been investigated the mechanism of internalization of BoNT/A. 
Electron microscopy experiments allowed us to visualize the internalization of 
BoNT/A into the lumen of small synaptic vesicles of NMJ ex vivo preparation. 
Moreover, by screening many replicates, we have reported that, along 
intoxication, there is an average value of 1.5 toxin molecules per vesicles. This 
fits very well with the estimation that a population of small synaptic vesicles 
contain an average of 1.7 SV2 molecules per each vesicle37 and underlines that it 
is the proteic receptor, rather than the polysialogangliosides, that induce the 
molecule internalization and trafficking. In addition, this finding supports the idea 
that L chain translocating channel is made of one, or at the most, two HN 
domains. Such evidence reinforces the concept of BoNT/A as a nanomachine4, 
which provides a model where each molecule is sufficient for the correct 
translocation of the own catalytic subunit. These considerations could be 
extended also to other toxins which exploits SV2 as proteic receptor. Recently, it 
has been reported by Sun and colleagues that BoNT/B and BoNT/E form a trimer 
and that the translocating channel is composed of three HN molecules160, 161. 
Oligomerization is of course possible in the case of BoNT/B which interacts with 
synaptotagmin I/II, present inside synaptic vesicles in many copies (average 
15.2)37. In the case of BoNT/E, the authors reported that oligomerization takes 
place on the plasma membrane, suggesting that, even if the number of SV2 
copies per vesicle is lower than three 37, the interaction of one molecule of the 
trimer with the luminal portion of SV2 is sufficient for the internalization of the 
neurotoxin receptor supercomplex. On the other hand, this cannot be the case of 
BoNT/A, since just one-two gold dots per vesicles are present. Moreover, the 
extreme potency of CNTs push the option of a non-cooperative translocation. 
We also demonstrated that the achievement of translocation competent 
environment is very rapid, with a kinetic compatible only with the rapid 
acidification which occurs in small synaptic vesicles162, 163. Therefore it can be 
stated that translocation occurs from SV and, accordingly it can be excluded that, 
as many bacterial toxins do, BoNT/A exploits other cytosolic acid compartments 
like those found along the endosomes pathway. 
The employment in human therapy remains one of the main goal concerning 
BoNTs research. Even if BoNT/A remains the first-choice toxin for human 
diseases treatment, sometimes intrinsic resistance as well as the development of 
antitoxin antibodies hamper its use. It is therefore important to explore the 
potential of other serotypes. The lack of reports citing human outbreaks of type C 
and D botulism is consistent with the fact that these serotypes are mainly 
correlated with animal botulism. BoNT/C and /D scarce susceptibility could be 
attributed either to poor absorption of these specific toxins from the human 
gastrointestinal tract or to resistance of human cholinergic nerve terminal to the 
activity of these toxins. Nevertheless, the latter hypothesis is for sure wrong, at 
least for BoNT/C, which has been found to be a good alternative to BoNT/A142, 146, 
147, 164. On the other hand, little is known about BoNT/D human susceptibility. We 
therefore decided to increase the knowledge in this field, by testing, for the first 
time, BoNT/D in human muscles through the electrophysiological evaluation of 
the compound muscular action potential (CMAP) amplitude. We demonstrated 
that this toxin serotype is very effective in mice either in vitro, ex vivo and in vivo 
but is poorly effective in in inducing human skeletal muscle paralysis. 
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